Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
crispr
crispr-cas9
editas medicine
gene editing
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
alphabet
andrew oxtoby
babies
base editing
boston
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
broad institute
broad institute of harvard and mit
brook byers
cas13
ceo
charles chu
clinical hold
clinical study
combination
commissioner
congress
crispr cas14
crispr therapeutics
What
cas
3
×
crispr
big
bio
editas
medicine
available
based
beam
biosciences
bosley's
bosley’s
bridge
bucks
ceo
cheaper
crime
departure
develop
diagnostics
editing
editor
exit
expects
faster
founders
gene
gotten
guiding
harvard
jump
katrine
mammoth
mass
moves
personnel
precise
roundup
scientists
set
Language
unset
Current search:
cas
×
biotech
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M